Business / Finance

RSS

Triple-S Management reports consolidated revenues of $584.8 million for first quarter 2014

Triple-S Management Corporation, the leading managed care company in Puerto Rico, today announced consolidated revenues of $584.8 million and consolidated operating income of $10.0 million for the three months ended March 31, 2014.

6 May 2014

Nu Skin Enterprises reports record revenue of $671.1M in first quarter 2014

Nu Skin Enterprises, Inc. today announced record first-quarter results with revenue of $671.1 million, a 24 percent improvement over the prior-year period. Revenue was negatively impacted 4 percent by foreign currency fluctuations.

6 May 2014

Akorn’s consolidated revenue increases $90.6M to 23% in first quarter 2014

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for the first quarter ended March 31, 2014.

6 May 2014

Bayer to purchase consumer care business of Merck & Co, signs co-development deal for sGC modulators

Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co., Inc., Whitehouse Station, NJ, USA, for a purchase price of USD 14.2 billion (EUR 10.4 billion).

6 May 2014

Cortland Capital Market Services opens new office in London

Cortland Capital Market Services, the privately held global financial services firm, today announced the opening of its London office and the appointment of Juliana Ritchie (Juliana Man) as its Head of Business Operations for Europe.

6 May 2014

Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.

6 May 2014

Debiopharm signs new license and research agreement with Yale University

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases.

6 May 2014

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.

6 May 2014

ViSalus reports top line sales growth of $57.4M in first quarter 2014

ViSalus, the weight-loss and fitness company known for its mission of Challenging the world…10 lbs. at a time through the PROJECT 10™ Challenge, today announced first quarter 2014 sales of $57.4 million.

2 May 2014

Aviv REIT acquires eight skilled nursing facilities in California and Texas

Aviv REIT, Inc. announced today it has acquired eight post-acute and long-term care skilled nursing facilities ("SNFs") in California and Texas, in three separate transactions for $70.7 million.

2 May 2014

Cambrex sales decrease by 11.2% in first quarter 2014

Cambrex Corporation reports results for the first quarter ended March 31, 2014.

2 May 2014

CVS Caremark net revenues increase 6.3% to $32.7 billion in Q1 2014

CVS Caremark Corporation today announced operating results for the three months ended March 31, 2014.

2 May 2014

Select Medical Holdings' net operating revenues increase 1.7% to $762.6 million in Q1 2014

Select Medical Holdings Corporation today announced results for its quarter ended March 31, 2014 and the declaration of a cash dividend.

2 May 2014

Genzyme, Cleveland Clinic partner to develop new therapeutic approaches for MS treatment

Genzyme, a Sanofi company, announced today the formation of a research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of MS.

30 Apr 2014

Entrada's technology and services to be integrated into Ingenious Med platform

Today Ingenious Med, provider of the nation's leading patient encounter platform, and Entrada, a leading provider of EHR-integrated, provider productivity solutions, announced a strategic partnership to seamlessly integrate Entrada's technology and services into the Ingenious Med platform, available soon to Ingenious Med's 25,000-plus health provider client base.

30 Apr 2014

OSI Systems reports revenues of $204 million for third quarter fiscal 2014

OSI Systems, Inc. today announced financial results for the third fiscal quarter ended March 31, 2014, including, among other things, the introduction of reporting Adjusted EBITDA, a discussion of which can be found below, under the caption, "New Presentation of Non-GAAP Financial Measure."

30 Apr 2014

Hospira’s net sales increase 6.3% to $1.1B in first quarter 2014

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today reported results for the first quarter ended March 31, 2014.

30 Apr 2014

Otonomy secures $49M in oversubscribed Series D round of financing

Otonomy, Inc., a biopharmaceutical company developing and commercializing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has secured $49 million in an oversubscribed Series D round of financing.

30 Apr 2014

FitLife Brands reports record revenue of $6.3M in first quarter 2014

FitLife Brands, Inc., an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition Products™ (NDS), PMD®, SirenLabs® and CoreActive® today announced financial results for the first quarter ended March 31, 2014.

30 Apr 2014

Actavis’ net revenue increases 40% to $2.66B in Q1 2014

Actavis plc today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013.

30 Apr 2014